Misha Amoils1, Carolyn S Lee2, John Sunwoo1, Sumaira Z Aasi2, Wendy Hara3, Jinah Kim4, Davud Sirjani1, A Dimitrios Colevas5, Anne Lynn S Chang2, Vasu Divi1. 1. Department of Otolaryngology, Stanford University Medical Center, Stanford, California. 2. Department of Dermatology, Stanford University Medical Center, Stanford, California. 3. Department of Radiation Oncology, Stanford University Medical Center, Stanford, California. 4. Department of Dermatopathology, Stanford University Medical Center, Stanford, California. 5. Department of Oncology, Stanford University Medical Center, Stanford, California.
Abstract
BACKGROUND: Data lacks to guide treatment of regionally metastatic cutaneous head and neck squamous cell carcinoma (HNSCC). METHODS: We conducted a retrospective review of 80 patients treated for regionally metastatic cutaneous HNSCC. The effect of various clinicopathologic variables on overall survival (OS) was investigated, in addition to outcomes by treatment modality. RESULTS: On multivariate regression, cutaneous primary >2 cm (p = .03) and extracapsular spread (ECS; p = .01) were significantly associated with decreased OS. Location of regional metastasis (neck vs parotid vs both) had no effect on OS (p = .2), nor did the presence of a cutaneous primary at the time of presentation (p = .9). The 3-year survival was 43%, 52%, and 49% for surgery alone, adjuvant radiation, and adjuvant chemoradiation, respectively. Fifty-one percent of patients had a recurrence of their disease. CONCLUSION: Regionally metastatic cutaneous HNSCC is an aggressive disease associated with high recurrence rates. Patients with tumors >2 cm and ECS have poorer OS despite adjuvant therapy.
BACKGROUND: Data lacks to guide treatment of regionally metastatic cutaneous head and neck squamous cell carcinoma (HNSCC). METHODS: We conducted a retrospective review of 80 patients treated for regionally metastatic cutaneous HNSCC. The effect of various clinicopathologic variables on overall survival (OS) was investigated, in addition to outcomes by treatment modality. RESULTS: On multivariate regression, cutaneous primary >2 cm (p = .03) and extracapsular spread (ECS; p = .01) were significantly associated with decreased OS. Location of regional metastasis (neck vs parotid vs both) had no effect on OS (p = .2), nor did the presence of a cutaneous primary at the time of presentation (p = .9). The 3-year survival was 43%, 52%, and 49% for surgery alone, adjuvant radiation, and adjuvant chemoradiation, respectively. Fifty-one percent of patients had a recurrence of their disease. CONCLUSION: Regionally metastatic cutaneous HNSCC is an aggressive disease associated with high recurrence rates. Patients with tumors >2 cm and ECS have poorer OS despite adjuvant therapy.
Authors: Patrick L Quinn; Jin K Kim; Vishnu Prasath; Neal Panse; Thomas J Knackstedt; Ravi J Chokshi Journal: Arch Dermatol Res Date: 2022-03-18 Impact factor: 3.017
Authors: Axel Sahovaler; Rohin J Krishnan; David H Yeh; Qi Zhou; David Palma; Kevin Fung; John Yoo; Anthony Nichols; S Danielle MacNeil Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-04-01 Impact factor: 6.223
Authors: A J G Leus; M Frie; M S Haisma; J B Terra; B E C Plaat; R J H M Steenbakkers; G B Halmos; E Rácz Journal: J Eur Acad Dermatol Venereol Date: 2020-03-30 Impact factor: 6.166
Authors: Stephanie Flukes; Sallie Long; Shivangi Lohia; Christopher A Barker; Lara A Dunn; Jennifer Cracchiolo; Ian Ganly; Snehal Patel; Marc A Cohen Journal: OTO Open Date: 2021-01-08